Yinzhou District Center for Disease Control and Prevention
Ningbo, Zhejiang, 315100, China
Location status: Recruiting
NCT Number: NCT05919056
The CRITICALLY study is a cluster randomized trial that will evaluate the effectiveness of a risk-based dynamic monitoring strategy for the primary prevention of cardiovascular high-risk Chinese adults.
Interested in participating?
Request Info40 year–79 year
All sexes
Interventional
Not applicable
Ningbo, Zhejiang, 315100, China
Location status: Recruiting
The objective of the study is to evaluate the effectiveness of a risk-based management strategy on cardiovascular risk scores (calculated by the 2019 WHO cardiovascular risk charts) in 24 months (Phase I) and the incidence of major adverse cardiovascular events in 60 months (Phase II). Totally 216 clinics in Yinzhou District, China will be randomized to the intervention or the control arms with usual care. The interventions supported by the web-based decision support system include (1) cardiovascular risk assessment, (2) dynamic risk monitoring, and (3) regular visits by the general practitioner every three months. Only usual care will be provided in the control arm. The primary outcome is the change in cardiovascular risk scores for Phase I and the incidence of the composite endpoint of coronary heart disease, stroke, heart failure and all-cause mortality for Phase II. If the comprehensive strategy is proven effective, it could provide evidence for the primary prevention of cardiovascular diseases using digital health technology.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., "for the management of dyslipidemia, to provide clear treatment targets for high-risk participants").
Time frame: 24 months after baseline
The change in cardiovascular risk scores calculated by 2019 WHO laboratory-based risk charts
Time frame: 60 months after baseline
Incidence of coronary heart disease, stroke, heart failure and all-cause mortality
Time frame: 24 months after baseline
the change in systolic blood pressure from baseline
Time frame: 24 months after baseline
the change in total cholesterol from baseline
Time frame: 24 months after baseline
the change in low-density lipoprotein cholesterol from baseline
Time frame: 60 months after baseline
Measured using the EuroQol-5 Dimensions-5L(EQ-5D)
Time frame: 60 months after baseline
the incremental cost-effectiveness ratio (ICER) of the management provided by the interventions compared to the usual care
Contact information is provided by the study sponsor or research team.
Peking University
Other
Cardiovascular Risk Assessment and dynamIc Monitoring-based Prevention Trial for prImary Care quALity evaLuation in Yinzhou
Acronym: CRITICALLY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07613099
Acute Lung Injury, Allogeneic Stem Cell Transplantation
Bethesda, Maryland, United States
View Trial DetailsNCT07081711
Aortic Diseases, Arrhythmias, Cardiac
Cleveland, Ohio, United States
View Trial DetailsNCT05169333
Cardiovascular Diseases, Cardiovascular Risk Factors
Bethesda, Maryland, United States
View Trial DetailsNCT04241328
Cardiovascular Diseases
Vienna, Austria
View Trial Details